<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159838">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02003794</url>
  </required_header>
  <id_info>
    <org_study_id>IVIS 001</org_study_id>
    <nct_id>NCT02003794</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS)</brief_title>
  <acronym>IVIS</acronym>
  <official_title>Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Council of Thailand (NRCT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the result of intravenous fluid in patients with acute ischemic stroke within 72
      hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to find the effect of early  IV fluid administration  to patients with acute
      ischemic stroke on the neurological outcome and to determine the side effects of intravenous
      fluids. Due to its cost effectiveness and wide accessibility, the possible application or
      use of IV fluid infusion as first line treatment can aide in the treatment of more acute
      ischemic stroke patients worldwide.  This novel information will aide physicians with more
      comprehensive understanding of the efficacy of utilizing IV fluid in future treatment plans
      for patients with acute ischemic stroke.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>NIHSS ≤ 4</measure>
    <time_frame>day 7 after treatment or on the day of discharge</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients with good outcome by NIHSS ≤ 4 at day 7 after treatment or on the day of discharge, which ever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRS ≤ 1</measure>
    <time_frame>day 7 after treatment or on the day of discharge</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients with mRS ≤ 1 at day 7 after treatment or on the day of discharge, which ever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS ≤ 4</measure>
    <time_frame>at day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients with mRS ≤ 4 at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS ≤ 1</measure>
    <time_frame>at day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients with mRS ≤ 1 at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of serum osmolarity</measure>
    <time_frame>at day 3 after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of change of serum osmolarity at day 3 after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>IV Fluid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.9% NaCl solution infusion: 100 ml/hr for three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No IV Fluid</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Not receive any intravenous fluid but can consume oral fluid normally for three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% NaCl solution</intervention_name>
    <description>0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.</description>
    <arm_group_label>IV Fluid</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age from 18-80 years

          2. NIHSS ≥ 1

          3. Diagnosis of acute ischemic stroke within 72 hours from stroke onset

          4. Enrollment into the study within 24 hours after hospital arrival

          5. Urine specific gravity level &lt; 1.030

          6. Patient consent

        Exclusion Criteria:

          1. Patients receiving &gt; 40 ml/hr IV fluid infusion over 3 hours

          2. Acute ischemic stroke caused cardiogenic embolism

          3. Urine specific gravity ≥ 1.030

          4. Large cerebral infarction area

               1. Infarction &gt; 1/3 of middle cerebral artery area

               2. Infarction &gt; 1/2 of cerebellar hemisphere

          5. NHISS ≥ 18

          6. Previous or current episode of atrial fibrillation

          7. Previous or current episode congestive heart failure

          8. Previous echocardiogram with ejection fraction &lt; 40%

          9. Previous or current episode of dilated cardiomyopathy

         10. Abnormal renal function GFR ≤ 60% or serum creatinine ≥ 2

         11. Modified Rankin scale before acute ischemic stroke ≥ 2

         12. Patients receiving intravenous thrombolysis

         13. NPO with need for IV fluid

         14. IV fluid infusion needed from any other causes

         15. Patients with poor prognosis with life expectancy &lt; 90 days

         16. Patients involved in other ongoing clinical studies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nijasri C Suwanwela, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Supparat Charnwut, RN</last_name>
    <phone>6622564655</phone>
    <email>fern2_95@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurauma Chutinet, MD</last_name>
    <phone>6622564655</phone>
    <email>aurauma@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Supparat Charnwut, RN</last_name>
      <phone>6622564655</phone>
      <email>fern2_95@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Aurauma Chutinet, MD</last_name>
      <phone>6622564655</phone>
      <email>aurauma@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nijasri C Suwanwela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Nijasri C Suwanwela</investigator_full_name>
    <investigator_title>Division of Neurology, Department of Medicine, Faculty of Medicine</investigator_title>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <keyword>intravenous fluid</keyword>
  <keyword>้hydration</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
